Hepatitis C virus genotypes in Serbia and Montenegro: The prevalence and clinical significance

Table 1 Age of patients with chronic hepatitis C infection according to genotypes

Genotype	n	Mean ± SD (yr)	Range (yr)
11	95	44 ± 12	21-65
2	6	36 ± 13	22-51
3	38	37 ± 10	23-62
4	11	32 ± 13	16-55
1b3a	11	31 ± 9	18-48
1b4	3	42 ± 11	33-54
Total	164	41 ± 12	16-65

¹Including 1b, 1a, 1ab and two non-determined subtypes.

Table 2 Univariate logistic regression analysis of HCV genotypes according to age equal/older than 40 years

Genotype	Significance	Exp (B)	Lower-Upper1
12	0.000	3.757	1.952-7.232
33	0.015	0.390	0.183-0.832
1b3a	0.036	0.187	0.039-0.896

¹95.0% CI for EXP (B);

²Including subtypes 1b (94.74%), 1a (1.05%), intra-genotype variant 1ab (2.1%), and non-determined subtypes (2.1%);

³3b subtype.

Table 3 Univariate logistic regression analysis of HCV genotypes according to patients with a history of intravenous drug abuse

Genotype	Significance	Exp (B)	Lower-Upper1
12	0.013	0.413	0.205-0.833
33	0.008	2.833	1.318-6.089

¹95.0% CI for EXP (B);

²Including subtypes 1b (96.7%), 1a (1.1%), intra-genotype variant 1ab (1.2%), and non-determined subtypes (2.2%);

³3b subtype.

Table 4 Multivariate logistic analysis of HCV genotype 1 according to age, high HCV RNA, fibrosis score and intravenous drug use (IVDU)

Variable	Significance	EXP (B)	Lower-Upper1
≥ 40 yr	0.000	3.747	1.952-7.232
High RNA	0.012	3.819	1.339-10.89
Fibrosis score ≥ 4	0.030	2.413	1.072-3.938
IVDU	0.013	0.413	0.205-0.833

¹95.0% CI for EXP (B).

Table 5 Multivariate logistic regression analysis of HCV genotype 3 according to age and intravenous drug use (IVDU)

Variable	Significance	Exp (B)	Lower-Upper1
Age ≥ 40 yr	0.015	0.390	0.183-0.832
IVDU	0.008	2.833	1.318-6.089

¹95.0% CI for EXP (B).